A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times
weekly to patients with leukemia or myelodysplastic syndromes.